Dedong Li

CAS Key Laboratory Of Pathogen Microbiology And Immunology
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

CX1/BtSY2 and BANAL-20-52 exhibit broader receptor binding and higher affinities to multiple animal ACE2 orthologs than SARS-CoV-2 prototype.

CX1/BtSY2 and BANAL-20-52 exhibit broader receptor binding and higher affinities to multiple animal ACE2 orthologs than SARS-CoV-2 prototype.

Journal: Journal of virology

Published: July 10, 2025

A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate.

A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate.

Journal: Journal of medical virology

Published: February 17, 2025

SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion.

SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion.

Journal: EBioMedicine

Published: November 14, 2024

Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera.

Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera.

Journal: NPJ vaccines

Published: July 10, 2024

Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.

Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.

Journal: Journal of virology

Published: April 09, 2024

Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris.

Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris.

Journal: PLoS pathogens

Published: March 06, 2024

Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.

Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.

Journal: Structure (London, England : 1993)

Published: February 05, 2024

Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.

Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 18, 2023

Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.

Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.

Journal: Med (New York, N.Y.)

Published: November 14, 2023

Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins.

Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins.

Journal: The EMBO journal

Published: October 21, 2023

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines.

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines.

Journal: The New England journal of medicine

Published: March 01, 2023

Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants.

Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants.

Journal: Nature communications

Published: November 15, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026